Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: Evidence from a retrospective study

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 147-154

  Campiglio, Manuela ^a   Bufalino, Rosaria ^a   Sandri, Marco ^a   Ferri, Elisa ^a   Aiello, Rosa Anna ^b   De Matteis, Andrea ^c   Mottolese, Marcella ^d   De Placido, Sabino ^e   Querzoli, Patrizia ^f   Jirillo, Antonio ^g   Bottini, Alberto ^h   Fantini, Manuela ⁱ   Bonetti, Andrea ^j   Pedani, Fulvia ^k   Mauri, Maria ^l   Molino, Annamaria ^m   Ferro, Antonella ⁿ   Pupa, Serenella M ^a   Sasso, Marianna ^a   Ménard, Sylvie ^a   Balsari, Andrea ^o   Tagliabue, Elda ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Humanitas Centro Catanese di Oncologia   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h CREMONA HOSPITAL   (Italy)

ⁱ Azianda USL Rimini   (Italy)

^j Ospedale Mater Salutis   (Italy)

^k MOLINETTE HOSPITAL   (Italy)

^l SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^m UNIVERSITY OF VERONA   (Italy)

ⁿ SANTA CHIARA HOSPITAL   (Italy)

^o UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

HER2; Metastatic breast cancer; Propensity score matching; RECIST; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; ITALY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VISCERAL METASTASIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959226810     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1484-4     Document Type: Article

References (26)

1. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
2. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Anton A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D (Pubitemid 46207001)
3. A Fabi G Metro G Ferretti D Giannarelli CS Di P Papaldo M Mottolese P Carlini A Felici M Russillo F Cognetti 2008 Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies Breast 17 499 505 18450443 10.1016/j.breast.2008.03.006
4. G Cancello E Montagna D D'Agostino M Giuliano A Giordano LG Di M Plaitano PS De M De Laurentiis 2008 Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer Breast Cancer Res 10 R60 18631394 10.1186/bcr2119
5. JM Extra EC Antoine A Vincent-Salomon T Delozier P Kerbrat A Bethune-Volters JP Guastalla M Spielmann L Mauriac JL Misset D Serin M Campone C Hebert C Remblier L Bergougnoux F Campana M Namer 2010 Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Oncologist 15 799 809 20671105 10.1634/theoncologist.2009-0029 1:CAS:528:DC%2BC3cXht1SqtbnM
6. F Montemurro S Redana G Viale G Sanna M Donadio G Valabrega C del Curto A Bottini G Botti TA Paolo dei ME Jacomuzzi BM Di S Danese M Clavarezza J Kulka PS Di A Durando A Sapino M Aglietta 2008 Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era Clin Breast Cancer 8 436 442 18952558 10.3816/CBC.2008.n.053 1:CAS:528:DC%2BD1cXhsVaiu77J
7. G Von Minckwitz A Du bois M Schmidt N Maass T Cufer FE de Jongh E Maartense C Zielinski M Kaufmann W Bauer KH Baumann MR Clemens R Duerr C Uleer M Andersson RC Stein V Nekljudova S Loibl 2009 Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 1999 2006 10.1200/JCO.2008.19.6618
8. KL Blackwell HJ Burstein AM Storniolo H Rugo G Sledge M Koehler C Ellis M Casey S Vukelja J Bischoff J Baselga J O'Shaughnessy 2010 Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 1124 1130 20124187 10.1200/JCO.2008.21.4437 1:CAS:528:DC%2BC3cXktF2ltLo%3D
9. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT Van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer I 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
10. PR Rosenbaum DB Rubin 1983 The central role of the propensity score in observational studies for causal effects Biometrika 70 41 55 10.1093/biomet/70.1.41
11. L Breiman 2001 Random forests Mach Learn 45 5 32 10.1023/A:1010933404324 (Pubitemid 32933532)
12. PC Austin P Grootendorst GM Anderson 2007 A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study Stat Med 26 734 753 16708349 10.1002/sim.2580 (Pubitemid 46206593)
13. DG Clayton 1978 A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence Biometrika 65 141 151 10.1093/biomet/65.1.141 (Pubitemid 8308396)
14. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS (2008) Random survival forests. Ann App Stat 2: 841-860
15. P Grambsch T Therneau 1994 Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 515 526 10.1093/biomet/81.3.515
16. SM Iacus G Porro 2007 Missing data imputation, matching and other applications of random recursive partitioning Comput Stat Data Anal 52 733 789 10.1016/j.csda.2006.12.036 (Pubitemid 47552603)
17. F Montemurro M Donadio M Clavarezza S Redana ME Jacomuzzi G Valabrega S Danese G Vietti-Ramus A Durando M Venturini M Aglietta 2006 Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy Oncologist 11 318 324 16614227 10.1634/theoncologist.11-4-318 1:CAS:528:DC%2BD28XhtFKqsb%2FJ
18. NL Spector KL Blackwell 2009 Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 5838 5847 19884552 10.1200/JCO.2009.22.1507 1:CAS:528:DC%2BC3cXhtVWitro%3D
19. R Gennari S Ménard F Fagnoni L Ponchio M Scelsi E Tagliabue F Castiglioni L Villani C Magalotti N Gibelli B Oliviero B Ballardini G Da Prada A Zambelli A Costa 2004 Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin Cancer Res 10 5650 5655 15355889 10.1158/1078-0432.CCR-04-0225 1:CAS:528:DC%2BD2cXntlOqtb8%3D (Pubitemid 39180938)
20. PP Pandolfi 2004 Breast cancer - loss of PTEN predicts resistance to treatment N Engl J Med 351 2337 2338 15564551 10.1056/NEJMcibr043143 1:CAS:528:DC%2BD2cXhtValtrrN (Pubitemid 39552753)
21. R Nahta T Takahashi NT Ueno MC Hung FJ Esteva 2004 P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 15173011 10.1158/0008-5472.CAN-03-3900 1:CAS:528:DC%2BD2cXksVKns7k%3D (Pubitemid 38697313)
22. M Scaltriti F Rojo A Ocana J Anido M Guzman J Cortes CS Di X Matias-Guiu S Cajal J Arribas J Baselga 2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer I 99 628 638 1:CAS:528:DC%2BD2sXlvVSktr4%3D (Pubitemid 47073544)
23. DL Shattuck JK Miller KL Carraway III C Sweeney 2008 Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells Cancer Res 68 1471 1477 18316611 10.1158/0008-5472.CAN-07-5962 1:CAS:528:DC%2BD1cXislagu70%3D (Pubitemid 351346855)
24. MM Mocanu Z Fazekas M Petras P Nagy Z Sebestyen J Isola J Timar JW Park G Vereb J Szollosi 2005 Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines Cancer Lett 227 201 212 16112423 10.1016/j.canlet.2005.01.028 1:CAS:528:DC%2BD2MXosVaisrs%3D (Pubitemid 41169934)
25. AB Motoyama NE Hynes HA Lane 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 3151 3158 12036928 1:CAS:528: DC%2BD38XksVyqs70%3D (Pubitemid 34602408)
26. C Shah TW Miller SK Wyatt ET McKinley MG Olivares V Sanchez DD Nolting JR Buck P Zhao MS Ansari RM Baldwin JC Gore R Schiff CL Arteaga HC Manning 2009 Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer Clin Cancer Res 15 4712 4721 19584166 10.1158/1078-0432.CCR-08-2635 1:CAS:528:DC%2BD1MXosV2ltbw%3D